Topical GHK-Cu Gel for Acute Skin Wound Healing
In plain words A Phase 2 study of GHK in people 18 to 55, run by Hudson Biotech. It plans to enroll about 60 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 55; healthy volunteers accepted. Conditions: Acute Standardized Cutaneous Wounds (Punch-biopsy Wounds).
- Age 18 to 55 years at screening.
- Healthy adult as determined by medical history and limited physical examination.
- Body mass index (BMI) 18.0 to 30.0 kg/m².
- Willing and able to comply with study visits and daily product application for 14 days.
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
GHK-Cu Gel (Copper(II)-peptide complex); vehicle Gel (placebo comparator)
Registered summary
This study will evaluate whether a topical gel containing GHK-Cu (a copper(II)-peptide complex) can safely speed up healing of small, standardized skin wounds in healthy adults compared with a matching vehicle gel. Participants will receive two small punch-biopsy wounds on the upper arm; each wound will be randomly assigned to receive GHK-Cu gel or vehicle gel under identical dressings. Wounds will be photographed and assessed over 3 weeks, with a follow-up visit to evaluate scar quality.
Where, as registered
No US site; China (1).